Načítá se...
Ipilimumab in prostate cancer
INTRODUCTION: Immune checkpoint inhibitors, such as ipilimumab, are a new class of immunotherapeutic agents that have shown significant efficacy in melanoma. A number of ongoing clinical trials are investigating the role of ipilimumab in prostate cancer, either alone or in combination with immunomod...
Uloženo v:
| Vydáno v: | Expert Opin Biol Ther |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2012
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6628899/ https://ncbi.nlm.nih.gov/pubmed/23265575 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14712598.2012.754421 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|